Evidence map›Paper›PMID 32281043›Full record

ArticleDigestive diseases and sciences2021

Selective Internal Radiation Therapy for Hepatocellular Carcinoma Across the Barcelona Clinic Liver Cancer Stages.

Carlos Moctezuma-Velazquez, Aldo J Montano-Loza, Judith Meza-Junco, Kelly Burak, Mang Ma, Vincent G Bain, Norman Kneteman, Phillipe Sarlieve, Richard J Owen

Abstract readEvaluation StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Carlos Moctezuma-VelazquezDivision of Gastroenterology, Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Avenida Vasco de Quiroga No 15, Seccion XVI, Tlalpan, 14080, Mexico City, Mexico.
Aldo J Montano-LozaDivision of Gastroenterology and Liver Unit, University of Alberta Hospital, 8440 112th Street, Edmonton, AB, T6G 2B7, Canada.
Judith Meza-JuncoDepartment of Medical Oncology, Cross Cancer Institute, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada.
Kelly BurakLiver Unit, University of Calgary, 1403 - 29 St. N.W., Calgary, AB, T2N 2T9, Canada.
Mang MaDivision of Gastroenterology and Liver Unit, University of Alberta Hospital, 8440 112th Street, Edmonton, AB, T6G 2B7, Canada.
Vincent G BainDivision of Gastroenterology and Liver Unit, University of Alberta Hospital, 8440 112th Street, Edmonton, AB, T6G 2B7, Canada.
Norman KnetemanDivision of Transplantation, Department of Surgery, University of Alberta Hospital, 8440 112th Street, Edmonton, AB, T6G 2B7, Canada.
Phillipe SarlieveDepartment of Radiology and Diagnostic Imaging, Walter Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440 112th Street, Edmonton, AB, T6G 2B7, Canada.
Richard J OwenDepartment of Radiology and Diagnostic Imaging, Walter Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440 112th Street, Edmonton, AB, T6G 2B7, Canada. rowen@ualberta.ca.
University of Alberta Hospital · CAInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is the second most common lethal cancer, and there is a need for effective therapies. Selective internal radiation therapy (SIRT) has been increasingly used, but is not supported by guidelines due to a lack of solid evidence.

aimsDetermine the efficacy and safety of SIRT in HCC across the Barcelona Clinic Liver Cancer (BCLC) stages A, B, and C.

methodsConsecutive patients that received SIRT between 2006 and 2016 at two centers in Canada were evaluated.

resultsWe analyzed 132 patients, 12 (9%), 62 (47%), and 58 (44%) belonged to BCLC stages A, B, and C; mean age was 61.2 (SD ± 9.2), and 89% were male. Median survival was 12.4 months (95% CI 9.6-16.6), and it was different across the stages: 59.7 (95% CI NA), 12.8 (95% CI 10.2-17.5), and 9.3 months (95% CI 5.9-11.8) in BCLC A, B, and C, respectively (p = 0.009). Independent factors associated with survival were previous HCC treatment (HR 2.01, 95% CI 1.23-3.27, p = 0.005), bi-lobar disease (HR 2.25, 95% CI 1.30-3.89, p = 0.003), ascites (HR 1.77, 95% CI 0.99-3.13, p = 0.05), neutrophil-to-lymphocyte ratio (HR 1.11, 95% CI 1.02-1.20, p = 0.01), Albumin-Bilirubin (ALBI) grade-3 (HR 2.69, 95% CI 1.22-5.92, p = 0.01), tumor thrombus (HR 2.95, 95% CI 1.65-5.24, p < 0.001), and disease control rate (HR 0.62, 95% CI 0.39-0.96, p = 0.03). Forty-four (33%) patients developed severe adverse events, and ALBI-3 was associated with higher risk of these events.

conclusionsSIRT has the potential to be used across the BCLC stages in cases with preserved liver function. When using it as a rescue treatment, one should consider variables reflecting liver function, HCC extension, and systemic inflammation, which are associated with mortality.

Indexed as

CanadaCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingRadiotherapy, Computer-AssistedRetrospective StudiesSurvival RateTreatment OutcomeCarcinoma hepatocellularEmbolizationLiver cirrhosisRadiotherapyTherapeutic

Identifiers

PMID32281043
OpenAlexW3016180521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.